Business Wire

Alipay+ Partners With ComfortDelGro To Enable The Acceptance Of Mobile Payments From Malaysia And South Korea On Board Its Taxis

9.6.2022 02:37:00 EEST | Business Wire | Press release

Share

ComfortDelGro Taxi and Alipay+ today announced a partnership that enables mobile payments from Malaysia and South Korea, namely the Touch ‘n Go eWallet and Kakao Pay, to be accepted as cashless payment options in all its Comfort and CityCab taxis. Users of these mobile wallets can pay for the cab fare simply through the wallet apps without the need to exchange currency.

ComfortDelGro Taxi is Singapore’s largest taxi operator with a combined fleet of about 9,000 Comfort and CityCab taxis. Apart from cash payment, all ComfortDelGro Taxis currently support about 20 different cashless payment methods.

Introduced by Ant Group in 2020, Alipay+ is a suite of global cross-border digital payments and marketing solutions designed to enable businesses, especially small and medium-sized businesses, to process a wide range of mobile payment methods and reach 1 billion regional and global consumers, through one-time integration and simple technical adaption. Other leading e-wallets supported by Alipay+ include GCash (Philippines), TrueMoney (Thailand), Alipay HK (Hong Kong SAR, China) and more.

ComfortDelGro Taxi’s CEO, Mr Jackson Chia said of this partnership: “With Singapore reopening its borders, we are looking forward to having tourists come visit us. As such, our partnership with Alipay+ is a vital one as it allows cashless payment options such as Malaysia’s Touch ‘n Go eWallet and soon South Korea’s Kakao Pay available on board ComfortDelGro taxis, making it more convenient for both Malaysian and South Korean tourists to pay for taxi fares. This saves them the hassle of having to have ready cash in local currency as they are able to pay the fares upfront on their own Touch ‘n Go eWallet or Kakao Pay App.”

Speaking of the collaboration, Ms Cherry Huang, General Manager, Global Merchant Partnership, South and Southeast Asia, Ant Group said: “Transportation is an essential daily need; taxi of all modes of transportation is even more important especially to travelers. Through the support and collaboration with ComfortDelGro Taxi, we aim to deliver to all users of mobile payments supported by Alipay+ a seamless and smart digital travel experience in Singapore, where they can pay with mobile wallets they are familiar with.”

“This partnership also comes at a great time, as Singapore leads the way in opening up its borders and welcomes tourists back in the city state. We believe this is the perfect moment for tourists to reimagine travel experience post pandemic,” she added.

According to the Singapore Tourism Board, the number of visitors to Singapore in the first four months of 2022 has exceeded figures for the whole of 20211. Malaysia is ranked #3 among the top countries where the most tourists are from. South Korea is also an important traveler source market for Singapore. In pre-COVID times, South Korea was ranked 9th out of the top 15 visitor source markets in 20192.

As part of a promotional campaign to commemorate this new collaboration, Touch ‘n Go eWallet users can enjoy instant discounts of RM4 or RM6 off their total fare when they pay for their rides using their Touch ‘n Go eWallet App from today until 25 June 2022. The discounts will vary in different weeks and are limited to the first 300 transactions daily.

About Ant Group

Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.

Ant Group is the owner and operator of Alipay, the leading digital payment platform in China serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.

Ant Group has further introduced Alipay+, which provides global cross-border mobile payments and marketing solutions that connect merchant partners, especially small and medium-sized businesses, with mobile payments and other payment methods, for them to better serve their users and customers from all over the world.

About ComfortDelGro Corporation Limited

ComfortDelGro is one of the world’s largest land transport companies with a total fleet size of about 35,000 buses, taxis and rental vehicles. We also run 177km of light and heavy rail networks in Singapore and New Zealand. Our global operations span seven countries – Singapore, Australia, the United Kingdom, New Zealand, China, Ireland and Malaysia. In Singapore, the Group operates about 9,000 Comfort and CtyCab taxis. For more information, visit www.comfortdelgro.com.

1 Source: The Straits Times (https://www.straitstimes.com/singapore/jan-april-tourist-numbers-exceed-arrivals-for-whole-of-2021-with-easing-of-border-curbs)
2 Source: Singapore Tourism Board (https://www.stb.gov.sg/content/stb/en/media-centre/media-releases/Singapore-Tourism-Board-and-Studio-Dragon-Corporation-forge-a-three-year-partnership-to-jointly-promote-Singapore-through-branded-content.html)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media

Betty Bai
Ant Group
M: +65 9183 9108
E: guzhuang.bb@antgroup.com

Yvonne Tang / Jaycelyn Choo
Group Corporate Communications
ComfortDelGro Corporation Limited
M: +65 9754 7670 / +65 9127 0468
E: groupcorpcomms@comfortdelgro.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye